WWWenhai Wang

Wenhai Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wenhai Wang has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Thrombolytic therapy efficacy in cardiopulmonary resuscitation: Investigating the effect of recombinant tissue plasminogen activator (Review)

    by Wenbin Zhang, Yinpng Pan, Jian Ding, Dexin Xu, Wenhai Wang

    Cardiopulmonary resuscitation (CPR) involves a series of urgent life‑saving actions performed to manually revive a person in cardiac arrest. In >70% of CPR cases, the primary health deterioration is due to acute myocardial infarction or a significant pulmonary embolism. Fibrinolytic therapy, also known as thrombolytic treatment, functions by dissolving dangerous intravascular clots to mitigate ischemic damage through improved blood circulation. Thrombolytic therapy has emerged as a promising intervention within the context of CPR for patients experiencing cardiac arrest. Recombinant tissue plasminogen activator (rtPA) is a bioengineered version of a natural enzyme that converts plasminogen into plasmin, an enzyme essential for clot dissolution. The efficacy of rtPA in thrombolytic therapy for CPR suggests its potential as a valuable clinical tool. The present comprehensive review assessed the efficacy and safety of rtPA administration during CPR, focusing on outcomes such as survival rates, neurological function and potential complications. It also explored the underlying mechanisms by which rtPA may enhance reperfusion and improve patient outcomes, including clot dissolution, myocardial salvage and microcirculatory improvements. Additionally, it examined the optimal timing and dosing strategies for rtPA administration and its integration with standard CPR protocols and other supportive therapies.


  • Nanotechnology Innovations in Myocardial Infarction: Diagnosis, Treatment and the Way Forward

    by Wenhai Wang, Dexin Xu, Jian Ding, Yinping Pan, Fang Wang, Shu Su, Xia Peng, Shitong Zhang, Wenbin Zhang

    Myocardial infarction (MI) is a global health concern that necessitates continued advancements in diagnostic and therapeutic modalities. Nanotechnology facilitates prompt diagnosis and personalized treatment. This manuscript explicitly reviews the application of innovative methodologies for identifying cardiac biomarkers to facilitate the early diagnosis of MI and its clinical management. Nanoscale agents such as nanoparticles and nanosensors have been employed for this purpose. Technological advancements in medical imaging are revolutionizing therapeutic approaches while reducing morbidity and mortality typically associated with cardiac tissue injury. Besides all, applications of nanotechnology in therapeutics have proven extremely effective. The development of nanoparticle-based customized drug delivery systems will contribute to more effective treatments, fewer side effects, and improved therapeutic outcomes. Biomaterials and nanoscale surgical technologies may benefit patients with MI by promoting tissue regeneration and repair. This manuscript also investigates the ethical and legal limitations that could prevent seamless incorporation of nanotechnology into clinical practice. Graphical Abstract


  • Ultrasound-Guided Radiofrequency and Microwave Ablation for the Management of Patients With Benign Thyroid Nodules

    by Jian Mm Ding, Duo Mm Wang, Wenbin Mm Zhang, Dexin Mm Xu, Wenhai Mm Wang

    Ultrasound-guided thermal ablation has been shown to considerably reduce nodule-related discomfort and cosmetic problems. Hence, this review was done to determine the effectiveness of ultrasound-guided radiofrequency or microwave ablation in the management of benign thyroid nodules. Searches were done in EMBASE, SCOPUS, PubMed Central, Cochrane library, MEDLINE, Google Scholar, ScienceDirect, and Clinicaltrials.gov until August 2022. Meta-analysis was carried out using random-effects model. With 95% confidence intervals (CIs), pooled standardized mean differences, mean differences, and/or odds ratio reported. In total, we analyzed 16 studies, most of them had high risk of bias. The pooled standardized mean difference for symptom score was −1.01 (95% CI, −1.83 to −0.19; I 2 = 94.2%), for cosmetic relief was −1.26 (95% CI, −2.27 to −0.24; I 2 = 96%), for postoperative nodule volume was −1.77 (95% CI, −3.06 to −0.48; I 2 = 94%), for hospital stay was −3.88 (95% CI, −4.58 to −3.18; I 2 = 91.1%), for operation time was −3.30 (95% CI, −3.95 to −2.64; I 2 = 93.4%). The pooled odds ratio for postoperative pain was 0.04 (95% CI, 0.00–0.35; I 2 = 95.1%), for postoperative hypothyroidism was 0.04 (95% CI, 0.01–0.11; I 2 = 0%), for postoperative hoarseness was 0.56 (95% CI, 0.22–1.47; I 2 = 0%), for postoperative hematoma was 0.57 (95% CI, 0.15–2.22; I 2 = 0%). Ultrasound-guided radiofrequency and microwave ablation had better efficacy and safety profile in terms of symptoms, cosmetic relief, complication rate, duration of stay, and operation time when compared with conventional surgery or observation without treatment for patients with benign thyroid nodules.